Reporting adverse drug events to the Therapeutic Goods Administration.
作者信息
Martin Jennifer H, Lucas Catherine
机构信息
Discipline of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, New South Wales.
Hunter New England Health, Newcastle, New South Wales.
出版信息
Aust Prescr. 2021 Feb;44(1):2-3. doi: 10.18773/austprescr.2020.077. Epub 2021 Feb 1.
Abstract
摘要
相似文献
1
Reporting adverse drug events to the Therapeutic Goods Administration.
Aust Prescr. 2021 Feb;44(1):2-3. doi: 10.18773/austprescr.2020.077. Epub 2021 Feb 1.
2
Healthcare personnel's experience of reporting adverse drug reactions in Baghdad city: cross-sectional study.
Int J Clin Pharm. 2019 Oct;41(5):1307-1313. doi: 10.1007/s11096-019-00867-7. Epub 2019 Jun 25.
3
Annual report: surveillance of adverse events following immunisation in Australia, 2009.
Commun Dis Intell Q Rep. 2010 Sep;34(3):259-76.
4
Effect of the black triangle scheme and its online educational campaign on the quantity and quality of adverse drug event reporting in Australia: a time series analysis.
Expert Opin Drug Saf. 2020 Jun;19(6):747-753. doi: 10.1080/14740338.2020.1746762. Epub 2020 Mar 31.
5
Allergic reactions to Japanese encephalitis vaccine.
Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. doi: 10.1016/s0889-8561(03)00102-4.
6
Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Pharmacotherapy. 2018 Aug;38(8):785-793. doi: 10.1002/phar.2152. Epub 2018 Jul 13.
7
Surveillance of adverse events following immunisation in Australia annual report, 2016.
Commun Dis Intell (2018). 2018;42. Epub 2018 Nov 16.
8
A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.
J Clin Pharm Ther. 2012 Apr;37(2):148-52. doi: 10.1111/j.1365-2710.2011.01258.x. Epub 2011 May 18.
9
Improving the reporting of adverse drug reactions in the hospital setting.
Postgrad Med. 2010 Nov;122(6):154-64. doi: 10.3810/pgm.2010.11.2233.
10
Adverse Drug Event Reporting Rates After the Implementation of an EHR Integrated Reporting System.
Stud Health Technol Inform. 2019 Aug 21;264:1652-1653. doi: 10.3233/SHTI190580.
引用本文的文献
1
Strengthening Dental Materiovigilance: A Review of International Reporting Frameworks.
Int Dent J. 2025 Aug 6;75(5):100943. doi: 10.1016/j.identj.2025.100943.
2
Exploring Complementary Medicine Usage, Consumer Perceptions, and Impact of Label Warnings: A Cross-Sectional Study in Melbourne, Australia.
Pharmacy (Basel). 2025 Apr 27;13(3):61. doi: 10.3390/pharmacy13030061.
3
Co-Designing a Consumer-Focused Digital Reporting Health Platform to Improve Adverse Medicine Event Reporting: Protocol for a Multimethod Research Project (the ReMedi Project).
JMIR Res Protoc. 2025 Jan 15;14:e60084. doi: 10.2196/60084.
4
Consumers' knowledge and experiences of adverse drug reaction reporting in Australia: a national survey.
Eur J Clin Pharmacol. 2024 Oct;80(10):1543-1554. doi: 10.1007/s00228-024-03729-y. Epub 2024 Jul 12.
5
TGA and -back to the future (take 2).
Aust Prescr. 2024 Feb;47(1):29. doi: 10.18773/austprescr.2024.003.
6
Limitations of randomised controlled trials as evidence of drug safety.
Aust Prescr. 2023 Aug;46(2):22-23. doi: 10.18773/austprescr.2023.005.
7
Sustained Decline of Direct General Practitioner Reporting of Adverse Drug Reactions in Australia and Paucity in Details of Australian Reports in Safety Advisories.
Drug Saf. 2023 Jul;46(7):703-710. doi: 10.1007/s40264-023-01321-4. Epub 2023 Jun 2.
8
Consumer-Generated Discourse on Cannabis as a Medicine: Scoping Review of Techniques.
J Med Internet Res. 2022 Nov 16;24(11):e35974. doi: 10.2196/35974.
9
Vaccine safety: what systems are required to ensure public confidence in vaccines?
Med J Aust. 2022 Aug 15;217(4):189-190. doi: 10.5694/mja2.51662. Epub 2022 Jul 17.
10
NSW Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes.
Intern Med J. 2022 Feb;52(2):228-237. doi: 10.1111/imj.15635. Epub 2022 Feb 10.
本文引用的文献
1
Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model.
Br J Clin Pharmacol. 2020 Dec;86(12):2530-2534. doi: 10.1111/bcp.14099. Epub 2019 Oct 17.
2
Defining and classifying terminology for medication harm: a call for consensus.
Eur J Clin Pharmacol. 2019 Feb;75(2):137-145. doi: 10.1007/s00228-018-2567-5. Epub 2018 Oct 11.
3
Pharmacovigilance and expedited drug approvals.
Aust Prescr. 2018 Apr;41(2):50-53. doi: 10.18773/austprescr.2018.010. Epub 2018 Apr 3.
4
Improving reporting of adverse drug reactions: Systematic review.
Clin Epidemiol. 2009 Aug 9;1:75-92. doi: 10.2147/clep.s4775.
5
Widespread hyoscine hydrobromide toxicity due to contract manufacturer malpractice : the travacalm episode.
Drug Saf. 2007;30(5):375-8. doi: 10.2165/00002018-200730050-00002.
6
Under-reporting of adverse drug reactions : a systematic review.
Drug Saf. 2006;29(5):385-96. doi: 10.2165/00002018-200629050-00003.
7
Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital.
Br J Clin Pharmacol. 2005 Dec;60(6):653-8. doi: 10.1111/j.1365-2125.2005.02504.x.
8
A method for estimating the probability of adverse drug reactions.
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
Zotero 插件